TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Hamilton Depression Rating Scale (HamD) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change in HbA(1c) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hospitalization for congestive heart failure (CHF)
Endpoint domain: Adverse events/effects
Primary endpoint: Attention and working memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: HOMA-B improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: disappearance time of principal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative conversion rate of rotavirus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum levels of IgA and IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: fewer uncovered struts per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: thicker neointimal hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Hydrocarbon concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in EASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of etoposide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma threonine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma total alkaline phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum osteocalcin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma ICTP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DPA SF-8 correlation with DPA scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DPA SF-10 correlation with DPA scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: stool consistency ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of medically-confirmed adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of adverse events (leukopenia, anaemia, anorexia, nausea/vomiting, stomatitis, alopecia)
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuropsychiatric symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of demands for analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of migraine relapse or aggravation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: summed pain intensity difference over 8 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total pain relief over 8 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate control of ventricular rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacological conversion to sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall rates of cardioversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary 8‐OHdG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal incision enlargement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: caregiver self-efficacy for cancer symptom management
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: caregiver self-efficacy for stress management
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: caregiver preparedness for caregiving
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Wandering rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive emotional expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative emotional expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin closing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction of ulcer area covered by fibrin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time with BIS between 40 and 60
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed to tracheal extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Persistence of reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction of symptom intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort during administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biochemical relapse as determined by prostate specific antigen
Endpoint domain: Mortality/survival
Primary endpoint: metastasis
Endpoint domain: Mortality/survival
Primary endpoint: dyspnea score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: overall symptom score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: throat pain resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Orofacial airway dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: methamphetamine use reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower bloating score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum alanine aminotransferase variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum aspartate aminotransferase variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum gamma‐glutamyl transpeptidase variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of complete analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Received social support for physical exercise
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: ETDRS VA scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement in macular edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute rejection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: motivation (confidence in ability to change)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: frequency of binge episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing rates of ESD-induced ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diminution rates of ESD-induced ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak E-wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in CIC symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incontinence rates at 3, 6, 9, and 12 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean rise in Haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance with supplementation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tidal volume depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: global score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of myometrial coring failure
Endpoint domain: Adverse events/effects
Primary endpoint: Average treatment cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Visual Acuity (VA) outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective cure rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall assessment of hayfever severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Late skin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum allergen-specific IgG4/IgE ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Pulmonary Arterial Pressure (mPAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: intrusive thoughts improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep quality improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy for discrimination of neoplastic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall survival probability at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Event-free survival probability at 5 years for those achieving CR
Endpoint domain: Mortality/survival
Primary endpoint: surgical site infections (SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Patient understanding of tests performed
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient understanding of post-discharge recommendations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Daily step count increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dominant tinnitus pitch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMD at Ward's triangle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atorvastatin AUC elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of life scales
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: percentage of complete motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nocturnal gastric acidity control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: median pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage of time pH > 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Colonization risk
Endpoint domain: Adverse events/effects
Primary endpoint: MCRI risk
Endpoint domain: Adverse events/effects
Primary endpoint: Heart rate-lowering effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnosable proportions of reconstruction images at mid-diastole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosable proportions of optimal reconstruction images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dietary calcium intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Milk consumption frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Meeting age-specific recommendations for daily calcium intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnosis of obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referral for diet treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Referral for exercise
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diagnostic yield of CE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial blood glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body slimming
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excessive scarring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mean peak plasma concentration of celiprolol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean area under the plasma celiprolol concentration‐time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary excretion of celiprolol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time on Task (TOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital Anxiety and Depression Scale-Anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hospital Anxiety and Depression Scale-Depression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: freedom from thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean rate of JSN in OA knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum plasma voriconazole concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration‐time curve of voriconazole (AUCtau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total time taken
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Circulating alarin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in NTX scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain interference in walking ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: emotional well being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time spent searching
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Days until long-term admission
Endpoint domain: Mortality/survival
Primary endpoint: Change in circulating total adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Added sugar intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Television viewing time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Absorbed dose in tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GAIS scores for gout attack intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American Board of Surgery In‐Training Examination scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualifying Examination pass rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Certifying Examination pass rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of flare-ups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total bilirubin (TBIL) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: indexes of hepatic fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Risk of thromboembolic events (TVEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: serum levels of total and low-density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Th17 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean load of administered iodine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean vascular enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: DPP IV inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of active GLP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: a.m./p.m. nasal congestion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TGF‐beta1 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal splitting of split components (SC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of split components (SC) recorded
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cough frequency by visual analogue scale
Endpoint domain: Adverse events/effects
Primary endpoint: complication score
Endpoint domain: Adverse events/effects
Primary endpoint: PC20 value increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Death at home
Endpoint domain: Mortality/survival
Primary endpoint: Symptom burden (weakness, fatigue, disorientation/confusion, appetite loss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delayed memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visuospatial ability improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean final core temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion rates of follow-up questionnaires
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Eosinophil cationic protein in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diastolic Blood Pressure (DBP) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: bleeding duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: body mass reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cardiorespiratory fitness (CRF) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity score in 28-joint count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American College of Rheumatology 20/50/70-based efficacy profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proatherogenic serum lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood pressure management adherence scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of (51)Cr-labeled RBCs
Endpoint domain: Mortality/survival
Primary endpoint: Primary graft dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Particle count increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean KOOS(4) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage of days with satisfactory symptom relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean CADSS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in pain during normal activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in central abdominal fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in lipid profile (VLDL cholesterol, total triglyceride, LDL particle size)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of SAD severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 AUC0‐4h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: rate of moderate or severe exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: Mean relative enhancements of liver parenchyma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of steps taken
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limb fat mass change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic perturbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: COX-2 mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Extracellular acidification rate (ECAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes